The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the predominant accumulation of four-repeat (4R) tau isoforms. These include Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17). While these disorders share the common feature of 4R tau accumulation, they exhibit distinct patterns of blood-brain barrier (BBB) dysfunction that contribute to disease progression and clinical heterogeneity.
The blood-brain barrier is a highly selective interface composed of endothelial cells connected by tight junctions, surrounded by pericytes, astrocytes end-feet, and the basement membrane. In 4R-tauopathies, BBB dysfunction has emerged as a critical pathological feature that may represent a common therapeutic target across these disorders.
| Disease | Primary Tau Pathology | BBB Findings | Key References |
|---|---|---|---|
| PSP | 4R tau in neurons/glia | Pericyte loss, TJ disruption | Montagne et al., 2020 |
| CBD | 4R tau, astrocytic plaques | Endothelial dysfunction | Forman et al., 2002 |
| AGD | 4R argyrophilic grains | Moderate BBB compromise | Togo et al., 2002 |
| GGT | 4R tau in glial cells | Perivascular tau, pericyte injury | Ahmed et al., 2007 |
| FTDP-17 | 3R+4R tau (MAPT mutations) | Variable BBB changes | Hutton et al., 2000 |
Pericytes are critical regulators of BBB integrity. In 4R-tauopathies, pericyte degeneration is a prominent feature:
PSP: Postmortem studies demonstrate 30-50% reduction in pericyte coverage, with elevated soluble PDGFRβ (sPDGFRβ) in CSF correlating with disease severity[1].
CBD: Pericyte loss accompanies astrocytic plaque formation, with PDGFRβ-immunoreactive pericytes showing degenerative changes in affected regions[2].
GGT: The distinctive globular tau inclusions in oligodendrocytes and astrocytes are associated with pericyte injury and microvascular degeneration[3].
AGD: Pericyte involvement is moderate compared to PSP, with perivascular hemosiderin deposition indicating chronic microhemorrhages[4].
Pericyte loss in 4R-tauopathies occurs through:
Endothelial cells in 4R-tauopathies exhibit:
| Disease | Endothelial Changes | Severity |
|---|---|---|
| PSP | Severe, particularly in basal ganglia | +++ |
| CBD | Moderate, cortical predilection | ++ |
| AGD | Mild-moderate, temporal lobe | ++ |
| GGT | Variable, white matter predominant | ++ |
| FTDP-17 | Mutation-dependent | + to +++ |
Tight junction proteins are fundamentally altered in 4R-tauopathies:
These alterations result in:
| Transporter | Function | Changes in 4R-Tauopathies |
|---|---|---|
| LRP1 | Aβ/tau clearance | Reduced expression |
| RAGE | Influx receptor | Increased expression |
| P-gp (ABCB1) | Efflux transporter | Decreased activity |
| GLUT1 | Glucose transport | Reduced, contributing to hypometabolism |
| Transferrin receptor | Iron transport | Variable changes |
Transport protein alterations:
Cerebrospinal fluid analysis in 4R-tauopathies reveals:
A distinctive feature of 4R-tauopathies is the relationship between tau pathology and cerebral vasculature:
PSP: Tau-positive neurofibrillary tangles cluster around deep gray matter vessels, with "coiled bodies" in perivascular oligodendrocytes. Perivascular tau correlates with BBB leakiness.
CBD: Astrocytic plaques often localize to perivascular regions, and tau pathology in endothelial cells has been documented[6].
GGT: The defining globular glial tau inclusions frequently cluster around vessels, and this pattern correlates with pericyte loss.
AGD: Argyrophilic grains show a predilection for limbic perivascular regions.
BBB dysfunction represents a convergent therapeutic target:
All 4R-tauopathies demonstrate:
| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---|---|---|---|---|---|
| Pericyte loss | +++ | ++ | ++ | ++ | +/++ |
| TJ disruption | +++ | ++ | ++ | ++ | +/++ |
| Perivascular tau | +++ | ++ | +++ | +++ | ++ |
| CSF biomarkers | +++ | ++ | + | +/++ | ++ |
Blood-brain barrier dysfunction is a consistent finding across 4R-tauopathies, with PSP showing the most severe involvement and shared mechanisms linking pericyte loss, endothelial dysfunction, and tau pathology. Understanding these commonalities may reveal therapeutic targets applicable to multiple 4R-tauopathies, potentially slowing disease progression through BBB stabilization.
Montagne et al. APOE4 leads to blood-brain barrier dysfunction (2020). 2020. ↩︎
Forman et al. Transgenic mouse model of tau pathology (2005). 2005. ↩︎
Ahmed et al. Globular glial tauopathy (2007). 2007. ↩︎
Togo et al. Argyrophilic grain disease (2002). 2002. ↩︎
Nation et al. Blood-brain barrier breakdown is an early biomarker (2019). 2019. ↩︎
Dickson et al. Corticobasal degeneration (2009). 2009. ↩︎